vs

Side-by-side financial comparison of Teradyne (TER) and DENTSPLY SIRONA Inc. (XRAY). Click either name above to swap in a different company.

Teradyne is the larger business by last-quarter revenue ($1.1B vs $961.0M, roughly 1.1× DENTSPLY SIRONA Inc.). Teradyne runs the higher net margin — 23.7% vs -15.2%, a 38.9% gap on every dollar of revenue. On growth, Teradyne posted the faster year-over-year revenue change (43.9% vs 6.2%). Teradyne produced more free cash flow last quarter ($218.8M vs $60.0M). Over the past eight quarters, Teradyne's revenue compounded faster (34.4% CAGR vs 0.4%).

Teradyne, Inc. is an American automatic test equipment (ATE) designer and manufacturer based in North Reading, Massachusetts. Its high-profile customers include Samsung, Qualcomm, Intel, Analog Devices, Texas Instruments and IBM.

Dentsply Sirona Inc. is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries. It has factories in 21 countries. The present company is largely the result of a merger in 1993 in which Gendex Corporation acquired Dentsply International Inc. for $590 million.

TER vs XRAY — Head-to-Head

Bigger by revenue
TER
TER
1.1× larger
TER
$1.1B
$961.0M
XRAY
Growing faster (revenue YoY)
TER
TER
+37.7% gap
TER
43.9%
6.2%
XRAY
Higher net margin
TER
TER
38.9% more per $
TER
23.7%
-15.2%
XRAY
More free cash flow
TER
TER
$158.8M more FCF
TER
$218.8M
$60.0M
XRAY
Faster 2-yr revenue CAGR
TER
TER
Annualised
TER
34.4%
0.4%
XRAY

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
TER
TER
XRAY
XRAY
Revenue
$1.1B
$961.0M
Net Profit
$257.2M
$-146.0M
Gross Margin
57.2%
46.1%
Operating Margin
27.1%
-14.5%
Net Margin
23.7%
-15.2%
Revenue YoY
43.9%
6.2%
Net Profit YoY
75.9%
66.0%
EPS (diluted)
$1.62
$-0.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
TER
TER
XRAY
XRAY
Q4 25
$1.1B
$961.0M
Q3 25
$769.2M
$904.0M
Q2 25
$651.8M
$936.0M
Q1 25
$685.7M
$879.0M
Q4 24
$752.9M
$905.0M
Q3 24
$737.3M
$951.0M
Q2 24
$729.9M
$984.0M
Q1 24
$599.8M
$953.0M
Net Profit
TER
TER
XRAY
XRAY
Q4 25
$257.2M
$-146.0M
Q3 25
$119.6M
$-427.0M
Q2 25
$78.4M
$-45.0M
Q1 25
$98.9M
$20.0M
Q4 24
$146.3M
$-430.0M
Q3 24
$145.6M
$-494.0M
Q2 24
$186.3M
$-4.0M
Q1 24
$64.2M
$18.0M
Gross Margin
TER
TER
XRAY
XRAY
Q4 25
57.2%
46.1%
Q3 25
58.4%
48.8%
Q2 25
57.2%
52.4%
Q1 25
60.6%
53.0%
Q4 24
59.4%
49.3%
Q3 24
59.2%
52.1%
Q2 24
58.3%
51.9%
Q1 24
56.6%
53.1%
Operating Margin
TER
TER
XRAY
XRAY
Q4 25
27.1%
-14.5%
Q3 25
18.9%
-24.1%
Q2 25
13.9%
-13.7%
Q1 25
17.6%
7.2%
Q4 24
20.4%
-56.2%
Q3 24
20.6%
-48.6%
Q2 24
28.8%
5.1%
Q1 24
13.0%
4.4%
Net Margin
TER
TER
XRAY
XRAY
Q4 25
23.7%
-15.2%
Q3 25
15.5%
-47.2%
Q2 25
12.0%
-4.8%
Q1 25
14.4%
2.3%
Q4 24
19.4%
-47.5%
Q3 24
19.8%
-51.9%
Q2 24
25.5%
-0.4%
Q1 24
10.7%
1.9%
EPS (diluted)
TER
TER
XRAY
XRAY
Q4 25
$1.62
$-0.74
Q3 25
$0.75
$-2.14
Q2 25
$0.49
$-0.22
Q1 25
$0.61
$0.10
Q4 24
$0.89
$-2.09
Q3 24
$0.89
$-2.46
Q2 24
$1.14
$-0.02
Q1 24
$0.40
$0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
TER
TER
XRAY
XRAY
Cash + ST InvestmentsLiquidity on hand
$293.8M
$326.0M
Total DebtLower is stronger
$2.3B
Stockholders' EquityBook value
$2.8B
$1.3B
Total Assets
$4.2B
$5.4B
Debt / EquityLower = less leverage
1.70×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
TER
TER
XRAY
XRAY
Q4 25
$293.8M
$326.0M
Q3 25
$272.7M
$363.0M
Q2 25
$339.3M
$359.0M
Q1 25
$475.6M
$398.0M
Q4 24
$553.4M
$272.0M
Q3 24
$510.0M
$296.0M
Q2 24
$421.9M
$279.0M
Q1 24
$707.4M
$291.0M
Total Debt
TER
TER
XRAY
XRAY
Q4 25
$2.3B
Q3 25
Q2 25
Q1 25
Q4 24
$1.7B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
TER
TER
XRAY
XRAY
Q4 25
$2.8B
$1.3B
Q3 25
$2.7B
$1.5B
Q2 25
$2.8B
$2.0B
Q1 25
$2.8B
$2.0B
Q4 24
$2.8B
$1.9B
Q3 24
$2.9B
$2.5B
Q2 24
$2.7B
$3.1B
Q1 24
$2.6B
$3.3B
Total Assets
TER
TER
XRAY
XRAY
Q4 25
$4.2B
$5.4B
Q3 25
$4.0B
$5.7B
Q2 25
$3.8B
$6.1B
Q1 25
$3.7B
$6.0B
Q4 24
$3.7B
$5.8B
Q3 24
$3.8B
$6.6B
Q2 24
$3.6B
$6.9B
Q1 24
$3.4B
$7.1B
Debt / Equity
TER
TER
XRAY
XRAY
Q4 25
1.70×
Q3 25
Q2 25
Q1 25
Q4 24
0.90×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
TER
TER
XRAY
XRAY
Operating Cash FlowLast quarter
$281.6M
$101.0M
Free Cash FlowOCF − Capex
$218.8M
$60.0M
FCF MarginFCF / Revenue
20.2%
6.2%
Capex IntensityCapex / Revenue
5.8%
4.3%
Cash ConversionOCF / Net Profit
1.09×
TTM Free Cash FlowTrailing 4 quarters
$450.4M
$104.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
TER
TER
XRAY
XRAY
Q4 25
$281.6M
$101.0M
Q3 25
$49.0M
$79.0M
Q2 25
$182.1M
$48.0M
Q1 25
$161.6M
$7.0M
Q4 24
$282.6M
$87.0M
Q3 24
$166.3M
$141.0M
Q2 24
$216.1M
$208.0M
Q1 24
$7.3M
$25.0M
Free Cash Flow
TER
TER
XRAY
XRAY
Q4 25
$218.8M
$60.0M
Q3 25
$2.4M
$40.0M
Q2 25
$131.7M
$16.0M
Q1 25
$97.6M
$-12.0M
Q4 24
$225.2M
$36.0M
Q3 24
$114.4M
$98.0M
Q2 24
$171.2M
$156.0M
Q1 24
$-36.7M
$-9.0M
FCF Margin
TER
TER
XRAY
XRAY
Q4 25
20.2%
6.2%
Q3 25
0.3%
4.4%
Q2 25
20.2%
1.7%
Q1 25
14.2%
-1.4%
Q4 24
29.9%
4.0%
Q3 24
15.5%
10.3%
Q2 24
23.5%
15.9%
Q1 24
-6.1%
-0.9%
Capex Intensity
TER
TER
XRAY
XRAY
Q4 25
5.8%
4.3%
Q3 25
6.1%
4.3%
Q2 25
7.7%
3.4%
Q1 25
9.3%
2.2%
Q4 24
7.6%
5.6%
Q3 24
7.0%
4.5%
Q2 24
6.1%
5.3%
Q1 24
7.3%
3.6%
Cash Conversion
TER
TER
XRAY
XRAY
Q4 25
1.09×
Q3 25
0.41×
Q2 25
2.32×
Q1 25
1.63×
0.35×
Q4 24
1.93×
Q3 24
1.14×
Q2 24
1.16×
Q1 24
0.11×
1.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

TER
TER

Soc$646.5M60%
Memory$206.5M19%
Transferred At Point In Time$90.0M8%
Universal Robots$89.4M8%
IST$30.5M3%
Transferred Over Time$20.5M2%

XRAY
XRAY

Essential Dental Solutions$372.0M39%
Equipment And Instruments$160.0M17%
Implants And Prosthetics$150.0M16%
CADCAM$139.0M14%
Wellspect Healthcare$88.0M9%
Orthodontics$52.0M5%

Related Comparisons